New: Introducing “Why Is It Moving?” - lightning-fast, AI-driven explanations of stock moves

Abeona Therapeutics Inc.

Contributing Author

Recent Articles by Abeona Therapeutics Inc.

Oct-01	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ABEO GlobeNewswire
Sep-02	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ABEO GlobeNewswire
Aug-29	Abeona Therapeutics Announces Participation in Upcoming Investor Conferences ABEO GlobeNewswire
Aug-14	Abeona Therapeutics Reports Second Quarter 2025 Financial Results and Corporate Updates ABEO GlobeNewswire
Aug-01	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ABEO GlobeNewswire
Jul-15	ZEVASKYN Gene Therapy Now Available at New Qualified Treatment Center in San Francisco Bay Area ABEO GlobeNewswire
Jul-02	Abeona Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $155 Million ABEO GlobeNewswire
Jul-01	Abeona Therapeutics Announces Option Exercise by Beacon Therapeutics for Novel AAV204 Capsid for Ophthalmology Gene Therapy ABEO GlobeNewswire
Jul-01	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ABEO GlobeNewswire
Jun-30	Abeona Therapeutics added to Membership of U.S. Small-cap Russell 2000 Index and Broad-market Russell 3000 Index ABEO GlobeNewswire
Jun-24	Abeona Therapeutics Announces Publication in The Lancet of Phase 3 VIITAL Study Data in Recessive Dystrophic Epidermolysis Bullosa ABEO GlobeNewswire
Jun-02	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ABEO GlobeNewswire
May-30	Abeona Therapeutics to Present at the Jefferies Global Healthcare Conference ABEO GlobeNewswire
May-15	Abeona Therapeutics Reports First Quarter 2025 Financial Results and Corporate Updates ABEO GlobeNewswire
May-14	UPDATE -- Abeona Therapeutics and Lurie Children's Open First Center for ZEVASKYN Gene Therapy to Treat Wounds in Painful Skin Disorder ABEO GlobeNewswire
May-14	Abeona Therapeutics and Lurie Children's Open First Center for ZEVASKYNTM Gene Therapy to Treat Wounds in Painful Skin Disorder ABEO GlobeNewswire
May-14	Abeona Therapeutics and Lurie Children's Open First Center for ZEVASKYN Gene Therapy to Treat Wounds in Painful Skin Disorder ABEO GlobeNewswire
May-12	Abeona Therapeutics Enters into Agreement to Sell Priority Review Voucher for $155 Million ABEO GlobeNewswire
May-07	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ABEO GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 FINVIZ.com. All Rights Reserved.